Zurich, September 29, 2025 – DiNAQOR AG, a global advanced medicines company builder, today congratulated Siegfried (SIX: SFZN) and its subsidiary DINAMIQS on the successful completion and inauguration of their new cGMP viral vector manufacturing facility in Switzerland. DINAMIQS was established in 2022 and spun out from DiNAQOR as an independent entity in 2023. Since then, it has been acquired with 95% equity by Siegfried, one of the leading Contract Development and Manufacturing Organizations (CDMOs).
The facility, inaugurated today, enables end-to-end viral vector manufacturing, from vector design and process development to aseptic drug product filling, and represents a milestone for Switzerland’s positioning in the cell and gene therapy sector.
Johannes Holzmeister, M.D., Executive Chairman and CEO of DiNAQOR AG, commented:
“Siegfried has done a truly outstanding job in growing DINAMIQS since the acquisition in 2023. With the inauguration of this new facility, DINAMIQS is now ready to deliver full end-to-end GMP manufacturing at the highest standard. This achievement creates significant synergies for DiNAQOR and our business partners, as we continue to develop transformative therapeutics and efficiently bring them to patients worldwide. We are proud to remain a minority equity holder and close partner of DINAMIQS.”
Martin Kessler, CEO of DINAMIQS, added:
“The ongoing partnership with DiNAQOR is very valuable. Their innovative programs in advanced medicines fit seamlessly with our expanded GMP capabilities, and together we are ideally positioned to help accelerate breakthrough therapies into the clinic.”
DiNAQOR, which initially founded DINAMIQS as part of its ongoing company-building strategy, continues to benefit from the strong partnership and its equity participation. The collaboration strengthens the overall ecosystem of DiNAQOR’s affiliates and business partners, ensuring they have access to world-class development and manufacturing capacity to match cutting-edge science.
About DiNAQOR
DiNAQOR is a pioneering biotech investor and builder with a proven track record of nurturing revolutionary technologies that have the potential to transform lives. Focusing on advanced and N=1 medicine, we leverage shared platforms and manufacturing expertise to cultivate innovative life science companies dedicated to solving complex medical challenges through organ-specific delivery, human-based tissue technologies, and patient-tailored solutions.
Guided by boldness and scientific curiosity, we challenge conventions and support and build companies from inception to full realization. Driven by a long-term vision and a broad network of business partners, our mission is to turn groundbreaking science into impactful solutions that shape the future of medicine.
Video of DINAMIQS’ new cGMP facility, please visit here.
For more information, please visit: www.dinaqor.com
Contact
Kaitlin Hart
DiNAQOR Group AG
info@dinaqor.com